Primera página del artículo de sobre bronquiectasias. THEODORE WILLIAMS, C. la fisiopatología de las bronquiectasias. El conocimiento acerca de. RESUMO: As bronquiectasias, outrora frequentes, têm vindo a tomarse numa situação patológia comparativamente rara. No entanto, a sua importância clínica . Las bronquiectasias no asociadas a fibrosis quística son una enfermedad compleja que ha despertado cada vez más interés científico debido a su creciente.

Author: Mobei Voodoogar
Country: Indonesia
Language: English (Spanish)
Genre: Health and Food
Published (Last): 22 August 2005
Pages: 493
PDF File Size: 4.69 Mb
ePub File Size: 12.18 Mb
ISBN: 154-2-95981-936-7
Downloads: 94963
Price: Free* [*Free Regsitration Required]
Uploader: Faejora

Polymicrobial airway bacterial communities in adult bronchiectasis patients. Effect of long-term, low-dose erythromycin on pulmonary exacerbations among patients with non-cystic fibrosis bronchiectasis: Bilateral bronchiectasis and bronchiolitis at thin-section CT: British Thoracic Society Research Committee. Ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis: Servicio de ayuda de la revista.

There was a problem providing the content you requested

Addition of inhaled tobramycin to ciprofloxacin for acute exacerbations of Pseudomonas aeruginosa infection in adult bronchiectasis.

Mechanisms of immune dysfunction and bacterial persistence in non-cystic fibrosis bronchiectasis. State of the art review: Systemic comorbidities in bronchiectasis. Chang AB, Bilton D.

Bronquiectasias | Blausen Medical

A prospective cohort analysis. The role of viral infection in pulmonary exacerbations of bronchiectasis bronquiectasais adults: Effect of sputum bacteriology on the quality of life of patients with bronchiectasis.


Prevalence of nontuberculous mycobacteria in patients with bronchiectasis: Assessing response to treatment of exacerbations of bronchiectasis in adults.

Effect of azithromycin maintenance treatment on infectious exacerbations among patients with non-cystic fibrosis bronchiectasis: Socioeconomic deprivation, readmissions, mortality and acute exacerbations of bronchiectasis.

Exacerbations in cystic fibrosis: Trace Elements and Host Defense: Bronchiectasis in a diverse US population. A novel microbiota ,as system predicts future exacerbations in bronchiectasis. British Thoracic Society guideline for non-CF bronchiectasis.


The effect of Pseudomonas aeruginosa on pulmonary function in patients with bronchiectasis. The bronchiectasis severity index. Tobramycin solution for inhalation reduces sputum Pseudomonas aeruginosa density in bronchiectasis. Combination inhaled corticosteroids and long-acting beta2-agonists for children and adults with bronchiectasis.

Cochrane Database Syst Rev.

Ann Am Thorac Soc. Prevalence and factors associated with isolation of Aspergillus and Candida fisiopatolotia sputum in patients with noncystic fibrosis bronchiectasis. Chest physiotherapy techniques in bronchiectasis.

Bronchiectasis-associated hospitalizations in Germany, Multidimensional approach to non-cystic fibrosis bronchiectasis: Inhaled steroids for bronchiectasis. Lung microbiota and bacterial abundance in patients with bronchiectasis when clinically stable and during exacerbation. A randomized controlled trial of nebulized gentamicin in non-cystic fibrosis bronchiectasis.

Inhaled colistin in patients with bronchiectasis and chronic Pseudomonas aeruginosa infection. The short and long term effects of exercise training in non-cystic fibrosis bronchiectasis–a randomised controlled trial. Pathological findings fisiopatologla bronchiectases caused by ycobacterium avium intracellulare complex. Vitamin-D deficiency is associated with chronic bacterial colonisation and disease severity fisiiopatologia bronchiectasis.


Treatment of idiopathic bronchiectasis with aerosolized recombinant human DNase I. Inhaled hyperosmolar agents for bronchiectasis.

Kellett F, Robert NM. Recent Advances and Continuing Challenges. Short- and long-term antibiotic treatment reduces airway and systemic inflammation in non-cystic fibrosis bronchiectasis.

Lung function, symptoms and inflammation during exacerbations of non-cystic fibrosis bronchiectasis: Microbiologic follow-up study in adult fisilpatologia. Ceftazidime compared with gentamicin and carbenicillin in patients with cystic fibrosis, pulmonary pseudomonas infection, and an exacerbation of respiratory symptoms.

Mortality in non-cystic fibrosis bronchiectasis: An international derivation and validation study. Clinical measures of disease in adult non-CF bronchiectasis correlate with airway microbiota composition.

Controlled trial of ceftazidime vs. Symptoms of airway reflux predict exacerbations and quality of life in bronchiectasis.